VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Post on 28-Dec-2015
215 Views
Preview:
Transcript
VBWG
OASIS-5OASIS-5
The Fifth The Fifth OOrganization to rganization to AAssess ssess SStrategies trategies in Acute in Acute IIschemic schemic SSyndromes trial yndromes trial
VBWG
US hospital discharges in ACS
AHA. Heart Disease and Stroke Statistics–2005 Update.
1.67 million hospital discharges/year
STEMI
1.17 million 500,000
Acute coronary syndromes
UA/NSTEMI
VBWG
OASIS-5: Background
• The combined use of anticoagulants, antiplatelet agents, and invasive coronary procedures in a routine early invasive strategy reduces ischemic coronary events but also increases bleeding in selected patients with ACS
• OASIS-5 was conducted to assess whether fondaparinux, a selective inhibitor of factor Xa, would preserve the anti-ischemic benefits of enoxaparin and further reduce bleeding
MICHELANGELO OASIS 5 Steering Committee. Am Heart J. 2005;150:1107-14.
OASIS-5 Investigators. N Engl J Med. 2006;354:1464-76.
VBWG
OASIS-5: Hypotheses
In the acute treatment of patients with UA/NSTEMIfondaparinux is:
• Noninferior to enoxaparin in preventing death, MI, or refractory ischemia through day 9
• Superior to enoxaparin as determined by lower major bleeding events through day 9
• Superior to enoxaparin in benefit/risk balance as determined by lower rate of death, MI, refractory ischemia, and major bleeding
MICHELANGELO OASIS 5 Steering Committee. Am Heart J. 2005;150:1107-14.
OASIS-5 Investigators. N Engl J Med. 2006;354:1464-76.
VBWG
OASIS-5: Study design
Patients with NSTE ACS, chest discomfort <24 hours,2: Age >60 y, ST segment, cardiac biomarkers
Outcomes
Primary: Efficacy Death, MI, refractory ischemia at 9 dSafety Major bleeding at 9 dBenefit/risk Death, MI, refractory ischemia, major bleeding at 9 d
Secondary: Primary outcomes plus each component at 30 d and 6 mo
MICHELANGELO OASIS 5 Steering Committee. Am Heart J. 2005;150:1107-14.
ASA, clopidogrel, GP IIb/IIIa,planned cath/PCI per local practice
Randomize
N = 20,078Fondaparinux2.5 mg sc qd
Enoxaparin1 mg/kg sc bid
VBWG
OASIS-5: Baseline characteristics
Enoxaparin(n = 10,021)
Fondaparinux(n = 10,057)
Age (years) 66.6 66.6
Male (%) 61.4 62.0
Time from pain onset (hours) 12.7 12.7
Heart rate (bpm) 73.0 73.0
Systolic BP (mm Hg) 136.3 136.6
Diagnosis at study entry (%) UA Suspected MI
45.154.9
45.654.4
OASIS-5 Investigators. N Engl J Med. 2006;354:1464-76.
VBWG
OASIS-5: Medical history
Enoxaparin(n = 10,021)
Fondaparinux(n = 10,057)
MI 25.7 25.7
PCI/CABG 19.5 20.1
Stroke 6.5 5.9
Heart failure 13.8 13.9
Hypertension 67.1 67.4
Diabetes 25.0 25.6
Current/former smoker 54.6 54.1
Any ECG abnormality 79.8 80.6
ST ≥1 mm 50.3 51.7
%
OASIS-5 Investigators. N Engl J Med. 2006;354:1464-76.
VBWG
OASIS-5: Concomitant in-hospital medications following randomization
Enoxaparin(n = 10,021)
Fondaparinux(n = 10,057)
ASA 97.5 97.5
Clopidogrel/ticlopidine 67.2 67.6
UFH 31.2 22.0
ACEI/ARB 76.1 74.9
β-blocker 87.7 87.2
Lipid-lowering agent 78.4 79.4
%
OASIS-5 Investigators. N Engl J Med. 2006;354:1464-76.
VBWG
OASIS-5: Treatment effect on primary efficacy outcome at 9 days
Death, MI, refractory ischemia
0 10
0.01
0.02
0.03
0.04
0.05
0.06
2 3
Enoxaparin
Cumulativeevent rate
Time (days)
Fondaparinux
4 5 6 7 8 9
HR 1.01 (0.90-1.13)
OASIS-5 Investigators. N Engl J Med. 2006;354:1464-76.
VBWG
OASIS-5: Treatment effect on primary safety outcome at 9 days
0.04
0.03
0.02
0.01
00 1 2 3 4 5 6 7 8 9
HR 0.52 (0.44-0.61)P < 0.001
Enoxaparin
Fondaparinux
Time (days)
0.06
Major bleeding
Cumulativeevent rate
OASIS-5 Investigators. N Engl J Med. 2006;354:1464-76.
VBWG
OASIS-5: Net clinical benefit at 9 days
Death, MI, refractory ischemia, major bleeding
0 1
0
0.02
0.04
0.06
0.08
2 3
Enoxaparin
Time (days)
Fondaparinux
4 5 6 7 8 9
HR 0.81 (0.73-0.89) P < 0.001
Cumulativeevent rate
OASIS-5 Investigators. N Engl J Med. 2006;354:1464-76.
VBWG
OASIS-5: Primary and secondary efficacy outcomes at 9 days
Prespecifiednoninferiority margin = 1.185
P = 0.007
RI = refractory ischemia
0.6 0.8 1 1.2
Hazard ratio (95% CI)
Fondaparinuxbetter
Enoxaparin better
Death/MI/RI
Death/MI
Death
MI
RI
5.8
4.1
1.8
2.6
1.9
Fondaparinux(n = 10,057)
5.7
4.1
1.9
2.7
1.9
Enoxaparin(n = 10,021)
%
OASIS-5 Investigators. N Engl J Med. 2006;354:1464-76.
VBWG
0.6 0.8 1 1.2
OASIS-5: Primary and secondary efficacy outcomes at 30 days
*P = 0.13†P = 0.02
Death/MI/RI*
Death/MI
Death†
MI
RI
Hazard ratio
8.0
6.2
2.9
3.9
2.2
Fondaparinux(n = 10,057)
8.6
6.8
3.5
4.1
2.2
Enoxaparin(n = 10,021)
%
Fondaparinuxbetter
Enoxaparin better
OASIS-5 Investigators. N Engl J Med. 2006;354:1464-76.
VBWG
OASIS-5: Death, MI, refractory ischemia at 6 months
0 20
0
0.02
0.04
0.06
0.08
0.10
0.12
0.14
40 60
Enoxaparin
Fondaparinux
80 100 120 140 160 180
HR 0.93(0.86-1.00) P = 0.06
Time (days)
Cumulativeevent rate
OASIS-5 Investigators. N Engl J Med. 2006;354:1464-76.
VBWG
OASIS-5: Net clinical benefit at 6 months
0 20
0
0.10
0.05
0.15
40 60
Enoxaparin
Time (days)
Fondaparinux
80 100 120 140 160 180
Death, MI, refractory ischemia, major bleeding
HR 0.86(0.81-0.93)P < 0.001
Cumulativeevent rate
0.20
OASIS-5 Investigators. N Engl J Med. 2006;354:1464-76.
VBWG
0.6 0.8 1 1.2
OASIS-5: Primary and secondary efficacy outcomes at 6 months
Death/MI/RI*
Death/MI†
Death†
MI
RI
Hazard ratio (95% CI)
13.2
11.4
6.5
6.6
2.4
Enoxaparin(n = 10,021)
%
Fondaparinuxbetter
Enoxaparin better
12.3
10.5
5.8
6.3
2.3
Fondaparinux(n = 10,057)
*P = 0.06†P = 0.05 OASIS-5 Investigators. N Engl J Med. 2006;354:1464-76.
VBWG
OASIS-5: Summary
• Primary outcome (death, MI, refractory ischemia)Fondaparinux was similar to enoxaparin in reducing the risk of ischemic events
• Primary safety outcomeRate of major bleeding was significantly lower for fondaparinux vs enoxaparin
• Benefit/risk assessmentRate of combined death, MI, refractory ischemia, and major bleeding was significantly lower for fondaparinux vs enoxaparin
At 9 days
OASIS-5 Investigators. N Engl J Med. 2006;354:1464-76.
VBWG
OASIS-5: Summary, cont’d
• Overall, durable long-term results were observed with fondaparinux vs enoxaparin; results occurred early and remained consistent through study end
– Strong trend toward lower rate of death, MI, or refractory ischemia at 30 days (P = 0.13) through 6 months (P = 0.06)
• Net clinical benefit in favor of fondaparinux at 6 months was demonstrated by significantly lower rate of combined death, MI, refractory ischemia, major bleeding (P < 0.001)
OASIS-5 Investigators. N Engl J Med. 2006;354:1464-76.
top related